Figure 14.
(A) Whole-body images at different time points after injection of 5550 MBq of [161Tb]Tb-PSMA-617. (B) Representative SPECT/CT sagittal and axial slices and CT axial slices demonstrating physiologic biodistribution in lacrimal, parotid, and submandibular glands; nasopharyngeal mucosa; liver; intestinal tract; kidneys; and urinary bladder, as well as pathologic uptake in primary prostate tumor and metastatic bone lesions. (p.i. = post-injection). Reprinted with permission from Al-Ibraheem et al. 96, copyright 2023 by the Society of Nuclear Medicine and Molecular Imaging.